Earnings Feed
Start Free
ROCKET PHARMACEUTICALS, INC.·4

Feb 20, 4:09 PM ET

Wilson Martin 4

Research Summary

AI-generated summary

Updated

Rocket Pharmaceuticals (RCKT) General Counsel Wilson Martin Sells 1,376 Shares

What Happened

Wilson Martin, General Counsel of Rocket Pharmaceuticals (RCKT), reported the sale of 1,376 shares of common stock on 2026-02-18 at $3.34 per share, for proceeds of $4,593. The filing notes this sale was made to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs), rather than a discretionary open-market investment decision.

Key Details

  • Transaction date and price: 2026-02-18 — 1,376 shares sold at $3.34 each.
  • Total proceeds: $4,593.
  • Shares owned after transaction: Not specified in the provided summary (filing may show total beneficial ownership, including unvested RSUs).
  • Footnotes:
    • F1: Holdings include RSUs that convert to common stock on a one-for-one basis.
    • F2: Shares were sold to pay tax withholding on vested RSUs (tax-withholding sale).
  • Filing: Form 4 filed 2026-02-20 for the 2026-02-18 transaction; no late filing flag indicated in the provided information.

Context

This was a routine sale to cover tax withholding tied to RSU vesting (a common practice), not a purchase or an exercise indicating added exposure. Such withholding sales generally reflect payroll/tax mechanics rather than a signal about the insider’s view on the company’s stock.